Friend or foe? Role of peroxisome proliferator-activated receptor-γ in human bladder cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 27, Issue 6, 2009, Pages 585-591

  Inamoto, Teruo ^a   Shah, Jay B ^a   Kamat, Ashish M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bladder cancer; Carcinogenesis; Peroxisome proliferator activated receptor; PPAR ; Rosiglitazone

Indexed keywords

15 DEOXY DELTA(12,14) PROSTAGLANDIN J2; 2 [1 CARBOXY 2 [4 [2 (5 METHYL 2 PHENYL 4 OXAZOLYL)ETHOXY]PHENYL]ETHYLAMINO]BENZOIC ACID METHYL ESTER; 2 CHLORO 5 NITROBENZANILIDE; BCG VACCINE; BEZAFIBRATE; CIGLITAZONE; CISPLATIN; ETALOCIB; GEMCITABINE; GLITAZONE DERIVATIVE; METHYLENE SUBSTITUTED DI INDOLYLMETHANE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; ROSIGLITAZONE; TROGLITAZONE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLADDER CANCER; BLADDER CARCINOGENESIS; CANCER CELL; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER INVASION; CELL PROLIFERATION; CELL VIABILITY; CHROMOSOME TRANSLOCATION 13; CHROMOSOME TRANSLOCATION 2; CIGARETTE SMOKING; COLON CANCER; DRUG ANTAGONISM; DRUG POTENTIATION; FRAMESHIFT MUTATION; HUMAN; MISSENSE MUTATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NONSENSE MUTATION; OCCUPATIONAL EXPOSURE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; TRANSURETHRAL RESECTION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCG VACCINE; DISEASE PROGRESSION; HUMANS; NEOPLASM INVASIVENESS; PPAR GAMMA; THIAZOLIDINEDIONES; URINARY BLADDER NEOPLASMS;

EID: 70350511393     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2008.11.002     Document Type: Review

References (72)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2007. CA: Cancer J Clin 57 (2007) 43-66
2. Dreicer R., Manola J., Roth B.J., et al. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Cancer 100 (2004) 1639-1645
3. Sternberg C.N., de Mulder P., Schornagel J.H., et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 42 (2006) 50-54
4. Eibl G., Reber H.A., Hines O.J., et al. COX and PPAR: Possible interactions in pancreatic cancer. Pancreas 29 (2004) 247-253
5. Gustafsson A., Hansson E., Kressner U., et al. EP1-4 subtype, COX, and PPAR γ receptor expression in colorectal cancer in prediction of disease-specific mortality. Int Journal Cancer 121 (2007) 232-240
6. Johnstone C.N., Mongroo P.S., Rich A.S., et al. Parvin-beta inhibits breast cancer tumorigenicity and promotes CDK9-mediated peroxisome proliferator-activated receptor γ 1 phosphorylation. Mol Cell Biol 28 (2008) 687-704
7. Koh W.P., Yuan J.M., Van Den Berg D., et al. Peroxisome proliferator-activated receptor (PPAR) γ gene polymorphisms and colorectal cancer risk among Chinese in Singapore. Carcinogenesis 27 (2006) 1797-1802
8. Morita D., Ichikura T., and Mochizuki H. The expression of PPAR γ in gastric cancer. Nippon Rinsho 59 Suppl 4 (2001) 595-597
9. Nagamine M., Okumura T., Tanno S., et al. PPAR γ ligand-induced apoptosis through a p53-dependent mechanism in human gastric cancer cells. Cancer science 94 (2003) 338-343
10. Radhakrishnan S.K., and Gartel A.L. The PPAR-γ agonist pioglitazone post-transcriptionally induces p21 in PC3 prostate cancer but not in other cell lines. Cell cycle (Georgetown) 4 (2005) 582-584
11. Wang X., Southard R.C., Allred C.D., et al. MAZ drives tumor-specific expression of PPAR γ 1 in breast cancer cells. Breast Cancer Res Treat 111 (2008) 103-111
12. Chinetti G., Fruchart J.C., and Staels B. Peroxisome proliferator-activated receptors (PPARs): Nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res 49 (2000) 497-505
13. Jump D.B., Clarke S.D., Thelen A., et al. Dietary fat, genes, and human health. Advances in experimental medicine and biology 422 (1997) 167-176
14. Telliez A., Furman C., Pommery N., et al. Mechanisms leading to COX-2 expression and COX-2 induced tumorigenesis: Topical therapeutic strategies targeting COX-2 expression and activity. Anticancer Agents Med Chem 6 (2006) 187-208
15. Grommes C., Landreth G.E., and Heneka M.T. Antineoplastic effects of peroxisome proliferator-activated receptor γ agonists. Lancet Oncol 5 (2004) 419-429
16. Nahle Z. PPAR trilogy from metabolism to cancer. Curr Opin Clin Nutr Metabolic Care 7 (2004) 397-402
17. Panigrahy D., Huang S., Kieran M.W., et al. PPARγ as a therapeutic target for tumor angiogenesis and metastasis. Cancer Biol Ther 4 (2005) 687-693
18. Peraza M.A., Burdick A.D., Marin H.E., et al. The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR). Toxicol Sci 90 (2006) 269-295
19. Rumi M.A., Ishihara S., Kazumori H., et al. Can PPARγ ligands be used in cancer therapy?. Cur Med Chem 4 (2004) 465-477
20. Corton J.C., Anderson S.P., and Stauber A. Central role of peroxisome proliferator-activated receptors in the actions of peroxisome proliferators. Annu Rev Pharmacol Toxicol 40 (2000) 491-518
21. Brun R.P., Tontonoz P., Forman B.M., et al. Differential activation of adipogenesis by multiple PPAR isoforms. Genes Dev 10 (1996) 974-984
22. Murad H., Collet P., Huin-Schohn C., et al. Effects of PPAR and RXR ligands in semaphorin 6B gene expression of human MCF-7 breast cancer cells. Int J Oncol 28 (2006) 977-984
23. Altiok S., Xu M., and Spiegelman B.M. PPARγ induces cell cycle withdrawal: Inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A. Genes Dev 11 (1997) 1987-1998
24. Budman D.R., and Calabro A. Studies of synergistic and antagonistic combinations of conventional cytotoxic agents with the multiple eicosanoid pathway modulator LY 293111. Anticancer Drugs 15 (2004) 877-881
25. Qin C., Morrow D., Stewart J., et al. A new class of peroxisome proliferator-activated receptor γ (PPARγ) agonists that inhibit growth of breast cancer cells: 1,1-Bis(3′-indolyl)-1-(p-substituted phenyl)methanes. Mol Cancer Ther 3 (2004) 247-260
26. Sato H., Ishihara S., Kawashima K., et al. Expression of peroxisome proliferator-activated receptor (PPAR)γ in gastric cancer and inhibitory effects of PPARγ agonists. Br J Cancer 83 (2000) 1394-1400
27. Yoshimura R., Matsuyama M., Segawa Y., et al. Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Int J Cancer 104 (2003) 597-602
28. Segawa Y., Yoshimura R., Hase T., et al. Expression of peroxisome proliferator-activated receptor (PPAR) in human prostate cancer. The Prostate 51 (2002) 108-116
29. Varley C.L., Garthwaite M.A., Cross W., et al. PPARγ-regulated tight junction development during human urothelial cytodifferentiation. J Cell Physiol 208 (2006) 407-417
30. Possati L., Rocchetti R., Talevi S., et al. The role of peroxisome proliferator-activated receptor γ in bladder cancer in relation to angiogenesis and progression. Gen Pharmacol 35 (2000) 269-275
31. Nakashiro K.I., Hayashi Y., Kita A., et al. Role of peroxisome proliferator-activated receptor γ and its ligands in non-neoplastic and neoplastic human urothelial cells. Am J Pathol 159 (2001) 591-597
32. Guan Y.F., Zhang Y.H., Breyer R.M., et al. Expression of peroxisome proliferator-activated receptor γ (PPARγ) in human transitional bladder cancer and its role in inducing cell death. Neoplasia (New York) 1 (1999) 330-339
33. Kroll T.G., Sarraf P., Pecciarini L., et al. PAX8-PPARγ1 fusion oncogene in human thyroid carcinoma [corrected]. Science (New York) 289 (2000) 1357-1360
34. Sarraf P., Mueller E., Smith W.M., et al. Loss-of-function mutations in PPAR γ associated with human colon cancer. Mol Cell 3 (1999) 799-804
35. Badawi A.F., Eldeen M.B., Liu Y., et al. Inhibition of rat mammary gland carcinogenesis by simultaneous targeting of cyclooxygenase-2 and peroxisome proliferator-activated receptor γ. Cancer Res 64 (2004) 1181-1189
36. Suh N., Wang Y., Williams C.R., et al. A new ligand for the peroxisome proliferator-activated receptor-γ (PPAR-γ), GW7845, inhibits rat mammary carcinogenesis. Cancer Res 59 (1999) 5671-5673
37. Tanaka T., Kohno H., Yoshitani S., et al. Ligands for peroxisome proliferator-activated receptors alpha and γ inhibit chemically induced colitis and formation of aberrant crypt foci in rats. Cancer Res 61 (2001) 2424-2428
38. Kohno H., Yoshitani S., Takashima S., et al. Troglitazone, a ligand for peroxisome proliferator-activated receptor γ, inhibits chemically-induced aberrant crypt foci in rats. Jpn J Cancer Res 92 (2001) 396-403
39. Lefebvre A.M., Chen I., Desreumaux P., et al. Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat Med 4 (1998) 1053-1057
40. Saez E., Tontonoz P., Nelson M.C., et al. Activators of the nuclear receptor PPARγ enhance colon polyp formation. Nat Medicine 4 (1998) 1058-1061
41. Cui Y., Miyoshi K., Claudio E., et al. Loss of the peroxisome proliferation-activated receptor γ (PPARγ) does not affect mammary development and propensity for tumor formation but leads to reduced fertility. J Biol Chem 277 (2002) 17830-17835
42. Takeda K., Ichiki T., Tokunou T., et al. 15-Deoxy-δ12,14-prostaglandin J2 and thiazolidinediones activate the MEK/ERK pathway through phosphatidylinositol 3-kinase in vascular smooth muscle cells. J Biol Chem 276 (2001) 48950-48955
43. Haraguchi K., Shimura H., and Onaya T. Activation of peroxisome proliferator-activated receptor-107 inhibits apoptosis induced by serum deprivation in LLC-PK1 cells. Exp Nephrol 10 (2002) 393-401
44. Wang Y.L., Frauwirth K.A., Rangwala S.M., et al. Thiazolidinedione activation of peroxisome proliferator-activated receptor γ can enhance mitochondrial potential and promote cell survival. J Biol Chemistry 277 (2002) 31781-31788
45. Leibovici D., Grossman H.B., Dinney C.P., et al. Polymorphisms in inflammation genes and bladder cancer: From initiation to recurrence, progression, and survival. J Clin Oncol 23 (2005) 5746-5756
46. Kassouf W., Chintharlapalli S., Abdelrahim M., et al. Inhibition of bladder tumor growth by 1,1-bis(3>29>-indolyl)-1-(p-substituted phenyl) methanes: A new class of peroxisome proliferator-activated receptor γ agonists. Cancer Res 66 (2006) 412-418
47. Fauconnet S., Lascombe I., Chabannes E., et al. Differential regulation of vascular endothelial growth factor expression by peroxisome proliferator-activated receptors in bladder cancer cells. J Biol Chem 277 (2002) 23534-23543
48. Ikeda E., Achen M.G., Breier G., et al. Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J Biol Chem 270 (1995) 19761-19766
49. Crew J.P., O'Brien T., Bradburn M., et al. Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res 57 (1997) 5281-5285
50. Zlotta A.R., van Vooren J.P., Huygen K., et al. What is the optimal regimen for BCG intravesical therapy?. Are six weekly instillations necessary?. Eur Urol 37 (2000) 470-477
51. Kamat A.M., and Dinney C.P. A combination of intravesical BCG [corrected] and [corrected] electromotive mitomycin for high-risk superficial bladder cancer. Nat Clin Pract 3 (2006) 472-473
52. Smith Jr. J.A., Labasky R.F., Cockett A.T., et al. Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1, and TIS). Am Urol Assoc, J Urol 162 (1999) 1697-1701
53. Oosterlinck W., Lobel B., Jakse G., et al. Guidelines on bladder cancer. Eur Urol 41 (2002) 105-112
54. Sylvester R.J., van der M.A., and Lamm D.L. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: A meta-analysis of the published results of randomized clinical trials. J Urol 168 (2002) 1964-1970
55. Lodillinsky C., Umerez M.S., Jasnis M.A., et al. Bacillus Calmette-Guerin induces the expression of peroxisome proliferator-activated receptor γ in bladder cancer cells. Int J Mol Med 17 (2006) 269-273
56. Kukreja A., Costi G., Marker J., et al. NKT cell defects in NOD mice suggest therapeutic opportunities. J Autoimmune 19 (2002) 117-128
57. Maclaren N., Lan M., Coutant R., et al. Only multiple autoantibodies to islet cells (ICA), insulin, GAD65, IA-2, and IA-2β predict immune-mediated (type 1) diabetes in relatives. J Autoimmune 12 (1999) 279-287
58. DuBois R.N., Gupta R., Brockman J., et al. The nuclear eicosanoid receptor, PPARγ, is aberrantly expressed in colonic cancers. Carcinogenesis 19 (1998) 49-53
59. Gupta R.A., Brockman J.A., Sarraf P., et al. Target genes of peroxisome proliferator-activated receptor γ in colorectal cancer cells. J Biol Chem 276 (2001) 29681-29687
60. Lehmann J.M., Moore L.B., Smith-Oliver T.A., et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J Biol Chem 270 (1995) 12953-12956
61. Panigrahy D., Shen L.Q., Kieran M.W., et al. Therapeutic potential of thiazolidinediones as anticancer agents. Expert Opin Investig Drugs 12 (2003) 1925-1937
62. Koeffler H.P., Sparkes R.S., Billing R., et al. Somatic cell hybrid analyses of hematopoietic differentiation. Blood 58 (1981) 1159-1163
63. Michalik L., Desvergne B., and Wahli W. Peroxisome-proliferator-activated receptors and cancers: Complex stories. Nat Rev 4 (2004) 61-70
64. Theocharisa S., Margeli A., and Kouraklis G. Peroxisome proliferator activated receptor-γ ligands as potent antineoplastic agents. Curr Med Chem 3 (2003) 239-251
65. Tontonoz P., Singer S., Forman B.M., et al. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor γ and the retinoid X receptor. Proc Natl Acad Sci USA 94 (1997) 237-241
66. Brockman J.A., Gupta R.A., and Dubois R.N. Activation of PPARγ leads to inhibition of anchorage-independent growth of human colorectal cancer cells. Gastroenterology 115 (1998) 1049-1055
67. Elstner E., Muller C., Koshizuka K., et al. Ligands for peroxisome proliferator-activated receptor γ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA 95 (1998) 8806-8811
68. Kubota T., Koshizuka K., Williamson E.A., et al. Ligand for peroxisome proliferator-activated receptor γ (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 58 (1998) 3344-3352
69. Sarraf P., Mueller E., Jones D., et al. Differentiation and reversal of malignant changes in colon cancer through PPARγ. Nat Med 4 (1998) 1046-1052
70. Gardner O.S., Dewar B.J., and Graves L.M. Activation of mitogen-activated protein kinases by peroxisome proliferator-activated receptor ligands: An example of nongenomic signaling. Mol Pharmacol 68 (2005) 933-941
71. Jain A., and Agus D.B. PPARγ signaling: One size fits all?. Cell Cycle (Georgetown) 3 (2004) 1352-1354
72. Rubenstrunk A., Hanf R., Hum D.W., et al. Safety issues and prospects for future generations of PPAR modulators. Biochim Biophys Acta 1771 (2007) 1065-1081